Аннотация:Background: The purpose of the study was to analyze the survival of patients with pancreatic cancer II-IV stages depending on the regimen used in the first line. Methods: The data of adults treated in 2013-2017 were studied. OS was calculated using the Kaplan Meier method and the log-rank test. Results: 133 pts were recruited: stage IIA – 26 (19.6%), IIB – 32 (24.1%), III – 29 (21.8%), IV – 46 (34.6%). The median survival was 7 mon (95% CI 1-11.8). The 36-month cumulative survival rate (CSR) was 0.2, and the 60-mon CSR – 0. Probability of surviving past 22 mon was 0.22, the standard error 0.09; past 12 mon – 0.45, the standard error 0.08. OS was associated with surgical treatment: 20-mon CSR with surgery – 0.25, without surgery – 0.4; 36-mon CSR – 0.25 and 0, respectively (p = 0.017). The median survival – 7 mon (95% CI 6.4-12.4) and 6 mon (95% CI 6.5-13.7), respectively. The median survival in st IIA was 6 mon (95% CI 4.2-12.3), IIB – 8 mon (95% CI 5.5-18.9), III – 6.5 mon (95% CI 4.1-14.8), IV - 6 mon (95% CI 4.7-13.7). 20-mon CSR in st IIA was 0.75, IIB – 0.4, III – 0.43, IV – 0.15 (p = 0.05). OS depended on the first-line therapy: 20-mon CSR in GEM/GEMCAP – 0.35 (median survival 6.5 mon, 95% CI 6.3-11.1), GEMOX – 0.28 (median survival 9 mon, 95% CI 6.2-16.8), FOLFOX/OXCAP/Capecitabin – 0.18 (median survival 3.5 mon, 95% CI 9.9-33.6), FOLFIRI/FOLFIRINOX – 0.36 (median survival 8 mon, 85% CI 8.5-33.2) (p = 0.01). Conclusions: The highest OS was registered in undergone surgery pts, pts with IIA stage of the disease and in pts with GEM/GEMCAP or FOLFIRI/FOLFIRINOX as the first-line therapy.